10x Genomics (TXG)
(Delayed Data from NSDQ)
$21.53 USD
+1.88 (9.57%)
Updated Aug 13, 2024 03:59 PM ET
After-Market: $21.54 +0.01 (0.05%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth D Momentum B VGM
10x Genomics (TXG) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$31.56 | $55.00 | $16.00 | 60.61% |
Price Target
Based on short-term price targets offered by 16 analysts, the average price target for 10x Genomics comes to $31.56. The forecasts range from a low of $16.00 to a high of $55.00. The average price target represents an increase of 60.61% from the last closing price of $19.65.
Analyst Price Targets (16)
Broker Rating
10x Genomics currently has an average brokerage recommendation (ABR) of 2.25 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 18 brokerage firms. The current ABR compares to an ABR of 2.36 a month ago based on 18 recommendations.
Of the 18 recommendations deriving the current ABR, seven are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 38.89% and 5.56% of all recommendations. A month ago, Strong Buy made up 33.33%, while Buy represented 5.56%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 7 | 7 | 6 | 10 | 10 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 9 | 9 | 10 | 6 | 5 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 1 | 1 | 1 | 1 | 1 |
ABR | 2.25 | 2.25 | 2.36 | 1.92 | 1.85 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/8/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
7/22/2024 | Not Identified | Not Identified | Hold | Strong Buy |
7/9/2024 | Goldman Sachs | Matthew Sykes | Strong Sell | Strong Sell |
6/27/2024 | Not Identified | Not Identified | Strong Buy | Hold |
6/25/2024 | Guggenheim Securities | Subbu Nambi | Strong Buy | Hold |
5/1/2024 | UBS | John N Sourbeer | Hold | Hold |
5/1/2024 | Cowen & Co. | Daniel Brennan | Strong Buy | Hold |
5/1/2024 | William Blair | Matt Larew | Hold | Hold |
5/1/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/1/2024 | Stephens | Mason Carrico | Strong Buy | Strong Buy |
4/29/2024 | Canaccord Genuity | Kyle Mikson | Strong Buy | Strong Buy |
4/15/2024 | CIBC World Markets Corp. | Bryce Adams | Not Available | Hold |
4/10/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
12/1/2023 | BMO Capital Markets | Kevin O'Halloran | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.25 |
ABR (Last week) | 2.25 |
# of Recs in ABR | 18 |
Average Target Price | $31.56 |
LT Growth Rate | 40.50% |
Industry | Medical Info Systems |
Industry Rank by ABR | 78 of 253 |
Current Quarter EPS Est: | -0.36 |